John Hussman's CPRX Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 147,000 shares of Catalyst Pharmaceuticals, Inc. (CPRX) worth $2.9 M, representing 0.63% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 18 quarters.
Based on 13F filings, John Hussman has maintained a strategic position in CPRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2023, adding 64,500 shares. Largest reduction occurred in Q3 2022, reducing 68,000 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Catalyst Pharmaceuticals (CPRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Catalyst Pharmaceuticals (CPRX) Trades by John Hussman
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2021 | +124,000 | New Buy | 124,000 | $5.75 |
| Q4 2021 | -56,000 | Reduce 45.16% | 68,000 | $6.76 |
| Q2 2022 | +62,000 | Add 91.18% | 130,000 | $7.01 |
| Q3 2022 | -68,000 | Reduce 52.31% | 62,000 | $12.82 |
| Q1 2023 | +31,000 | Add 50.00% | 93,000 | $16.58 |
| Q3 2023 | +64,500 | Add 69.35% | 157,500 | $11.69 |
| Q1 2024 | -52,500 | Reduce 33.33% | 105,000 | $15.94 |
| Q1 2025 | -21,000 | Reduce 20.00% | 84,000 | $24.25 |
| Q2 2025 | +63,000 | Add 75.00% | 147,000 | $21.70 |
John Hussman's Catalyst Pharmaceuticals Investment FAQs
John Hussman first purchased Catalyst Pharmaceuticals, Inc. (CPRX) in Q2 2021, acquiring 124,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Catalyst Pharmaceuticals, Inc. (CPRX) for 18 quarters since Q2 2021. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's largest addition to Catalyst Pharmaceuticals, Inc. (CPRX) was in Q2 2021, adding 124,000 shares worth $713,000. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 147,000 shares of Catalyst Pharmaceuticals, Inc. (CPRX), valued at approximately $2.9 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Catalyst Pharmaceuticals, Inc. (CPRX) represents approximately 0.63% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's peak holding in Catalyst Pharmaceuticals, Inc. (CPRX) was 157,500 shares, as reported at the end of Q3 2023. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.